Open Access

Parthenolide plays a protective role in the liver of mice with metabolic dysfunction‑associated fatty liver disease through the activation of the HIPPO pathway

  • Authors:
    • Weihong Wang
    • Yukai He
    • Qiuli Liu
  • View Affiliations

  • Published online on: April 29, 2021     https://doi.org/10.3892/mmr.2021.12126
  • Article Number: 487
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Metabolic dysfunction‑associated fatty liver disease (MAFLD) is a serious threat to human health. Parthenolide (PAR) displays several important pharmacological activities, including the promotion of liver function recovery during hepatitis. The aim of the present study was to assess the effect of PAR on MAFLD in a mouse model. Body weight, liver to body weight ratios, histological score, alanine transaminase, aspartate transaminase, total cholesterol and triglyceride levels were determined to evaluate liver injury. Liver hydroxyproline concentrations were also assessed. The expression levels of lipid metabolism‑related genes (sterol regulatory element binding protein‑1c, fatty acid synthase, acetyl CoA carboxylase 1, stearoyl CoA desaturase 1 and carbohydrate response element‑binding protein, peroxisome proliferator‑activated receptor α, carnitine palmitoyl transferase 1α and acyl‑CoA dehydrogenase short chain), liver fibrosis‑associated genes (α‑smooth muscle actin, tissue inhibitor of metalloproteinase 1 and TGF‑β1), pro‑inflammatory cytokines (TNF‑α, IL‑1β and IL‑6) and oxidative stress‑associated enzymes (malondialdehyde, superoxide dismutase and glutathione peroxidase) were measured in mice with MAFLD. The expression levels of genes associated with the HIPPO pathway were also measured. In vivo experiments using a specific inhibitor of HIPPO signalling were performed to verify the role of this pathway in the effects of PAR. PAR exerted beneficial effects on liver injury, lipid metabolism, fibrosis, inflammation and oxidative stress in mice with MAFLD, which was mediated by activation of the HIPPO pathway.

Related Articles

Journal Cover

July-2021
Volume 24 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang W, He Y and Liu Q: Parthenolide plays a protective role in the liver of mice with metabolic dysfunction‑associated fatty liver disease through the activation of the HIPPO pathway. Mol Med Rep 24: 487, 2021
APA
Wang, W., He, Y., & Liu, Q. (2021). Parthenolide plays a protective role in the liver of mice with metabolic dysfunction‑associated fatty liver disease through the activation of the HIPPO pathway. Molecular Medicine Reports, 24, 487. https://doi.org/10.3892/mmr.2021.12126
MLA
Wang, W., He, Y., Liu, Q."Parthenolide plays a protective role in the liver of mice with metabolic dysfunction‑associated fatty liver disease through the activation of the HIPPO pathway". Molecular Medicine Reports 24.1 (2021): 487.
Chicago
Wang, W., He, Y., Liu, Q."Parthenolide plays a protective role in the liver of mice with metabolic dysfunction‑associated fatty liver disease through the activation of the HIPPO pathway". Molecular Medicine Reports 24, no. 1 (2021): 487. https://doi.org/10.3892/mmr.2021.12126